Literature DB >> 9755091

Intrinsic mineralization defect in Hyp mouse osteoblasts.

Z S Xiao1, M Crenshaw, R Guo, T Nesbitt, M K Drezner, L D Quarles.   

Abstract

X-linked hypophosphatemia (XLH) is caused by inactivating mutations of PEX, an endopeptidase of uncertain function. This defect is shared by Hyp mice, the murine homologue of the human disease, in which a 3' Pex deletion has been documented. In the present study, we report that immortalized osteoblasts derived from the simian virus 40 (SV40) transgenic Hyp mouse (TMOb-Hyp) have an impaired capacity to mineralize extracellular matrix in vitro. Compared with immortalized osteoblasts from the SV40 transgenic normal mouse (TMOb-Nl), osteoblast cultures from the SV40 Hyp mouse exhibit diminished 45Ca accumulation into extracellular matrix (37 +/- 6 vs. 1,484 +/- 68 counts . min-1 . microgram protein-1) and reduced formation of mineralization nodules. Moreover, in coculture experiments, we found evidence that osteoblasts from the SV40 Hyp mouse produce a diffusible factor that blocks mineralization of extracellular matrix in normal osteoblasts. Our findings indicate that abnormal PEX in osteoblasts is associated with the accumulation of a factor(s) that inhibits mineralization of extracellular matrix in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755091     DOI: 10.1152/ajpendo.1998.275.4.E700

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  34 in total

1.  Evidence for a bone-kidney axis regulating phosphate homeostasis.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Bone, inflammation, and inflammatory bowel disease.

Authors:  Manasi Agrawal; Shitij Arora; Jianjun Li; Rabin Rahmani; Li Sun; Adam F Steinlauf; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

Review 3.  Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases.

Authors:  Fayez K Ghishan; Pawel R Kiela
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-18       Impact factor: 4.052

4.  Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization.

Authors:  Michael G Johnson; Jasmin Kristianto; Baozhi Yuan; Kathryn Konicke; Robert Blank
Journal:  Connect Tissue Res       Date:  2014-08       Impact factor: 3.417

5.  Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone.

Authors:  Monzur Murshed; Dympna Harmey; José Luis Millán; Marc D McKee; Gerard Karsenty
Journal:  Genes Dev       Date:  2005-04-15       Impact factor: 11.361

Review 6.  The genetic and molecular bases of monogenic disorders affecting proteolytic systems.

Authors:  I Richard
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 7.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

8.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

9.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

10.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.